Detalles de la búsqueda
1.
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
Br J Cancer
; 130(7): 1149-1156, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38308000
2.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 24(12): 1359-1374, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926100
3.
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.
Br J Cancer
; 129(5): 852-860, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37468569
4.
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage.
Health Qual Life Outcomes
; 18(1): 353, 2020 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33138835
5.
The rise of oncology biosimilars: from process to promise.
Future Oncol
; 15(28): 3255-3265, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31441323
6.
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
Oncologist
; 23(10): 1137-1143, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30018134
7.
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
Lancet Oncol
; 18(7): 929-945, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28600210
8.
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
Cancers (Basel)
; 14(11)2022 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35681574
9.
Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT).
BMJ Open
; 12(12): e066252, 2022 12 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36585130
10.
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Breast
; 66: 69-76, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36194950
11.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy.
Pharmacogenet Genomics
; 21(12): 808-19, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21946896
12.
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study.
Breast
; 60: 199-205, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34736090
13.
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Lancet
; 373(9676): 1681-92, 2009 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-19447249
14.
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
BMC Cancer
; 10: 337, 2010 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-20587042
15.
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
Clin Sarcoma Res
; 10: 9, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32391141
16.
A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
Clin Cancer Res
; 14(24): 8288-94, 2008 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19088046
17.
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
Clin Cancer Res
; 13(12): 3652-9, 2007 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17575230
18.
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.
Eur J Cancer
; 71: 15-24, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27940354
19.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Clin Cancer Res
; 11(21): 7834-40, 2005 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16278406
20.
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
Eur J Cancer
; 55: 27-37, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26773371